Replies to post #1886 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV 3Q20 Mavyret sales=$414M, +10% QoQ, -41% YoY:

As reported by GILD yesterday (#msg-159176251), COVID-19 continued to impede new-HCV-patient starts during 3Q20.

The 3Q20 Mavyret breakdown was: $185M US; $214M ex-US.

2020 Mavyret sales for the first nine months are now $1.34B.

PR:
https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2020-financial-results